10 August 2020

Freeline Therapeutics has announced the pricing of its initial public offering in the United States of 8,823,529 American Depositary Shares (“ADSs”) representing 8,823,529 ordinary shares at an initial public offering price of $18.00 per ADS for total gross proceeds of approximately $158.8 million.

The clinical-stage biotechnology company is focused on AAV-based gene therapy targeting the liver. It was founded in 2015, based on the research of Professor Amit Nathwani of the UCL Cancer Institute.

Read the announcement on the Freeline website.